TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A paper in The Lancet Healthy Longevity argues that age-related weakness and mobility loss should be understood as problems of the wider motor system, including the brain, nerves and muscle. The authors say muscle mass alone does not explain many changes in strength and function, but acknowledge that proposed assessment measures have not yet been shown to improve outcomes or costs.
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and mobility loss should be understood as changes across the motor system—not just declining muscle. Their proposal could broaden how clinicians assess sarcopenia, but the authors say the suggested measures still need testing before they can be adopted as better screening tools.
The paper, by Lucas B. R. Orssatto and colleagues, says muscle loss accounts for only a modest share of the decline in strength seen with age. People with similar amounts of muscle can have quite different strength and mobility, the authors note, while exercise can improve function even when measurable muscle mass does not change.
The motor system includes the brain and spinal cord, nerves, their connections to muscle, and muscle itself. The authors propose that age-related changes in movement planning, nerve signaling, balance and position sense can all contribute to weakness. They point to standing from a chair as an example: the task requires speed and power, not simply muscle bulk, and power can decline earlier and faster than muscle mass.
The authors outline a five-point agenda for international groups that set diagnostic criteria. They suggest retaining strength and walking-speed measures while also studying how quickly a person rises from a chair, steadiness during sustained effort, hand dexterity and walking while talking. They say clinicians should examine weakness more closely when it is asymmetric, rapid or out of proportion to muscle loss. The paper also recommends including medication review, because sedative and anticholinergic drugs can blunt motor drive.
A Broader View of Weakness
The proposal matters because sarcopenia is linked to frailty, disability and loss of independence, yet a muscle-focused explanation may not capture why a particular person is struggling to move. If the wider motor system contributes, assessments and research may need to examine more than muscle size and strength.
The potential public-health stakes are substantial in Australia, where the Medical Xpress report says there were 253,800 fall-related hospitalizations in 2024–25. It also reports 6,722 deaths following falls in the preceding year and an estimated $5.4 billion in health-system costs from fall injuries. These figures describe the Australian burden; they do not establish that the proposed motor-system approach would prevent falls or reduce costs.
The researchers say a broader framework could help direct research toward interventions that improve strength, movement and everyday function, rather than focusing predominantly on increasing muscle mass. That is a proposed direction, not a demonstrated result: the paper does not establish that new assessments or treatments based on the framework improve patient outcomes.
Products Worth Considering
Bose Lifestyle Ultra Wireless Home Speaker
Dyson Car+Boat Cordless Handheld Vacuum
Blueair Blue Pure 511i Max Smart Air Purifier
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Measures Have Changed
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The report says it affects up to 29% of community-dwelling older adults, with higher rates in hospitals, residential elder care and among people with multiple health conditions or frailty. The percentage is an estimate for that population and setting, not a universal rate for all older adults.
Diagnostic practice has already moved beyond muscle mass alone. According to the paper’s account, grip strength, gait speed and chair stands are used because they predict outcomes such as falls, disability and death better than muscle mass does. The authors argue that although the measurements have changed, explanations and research have continued to center heavily on muscle.
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm to help primary-care practices screen, assess and manage poor muscle health, Medical Xpress reported. The new paper adds a debate about what those assessments should capture. Its authors are asking international working groups to consider the motor system when they next revise diagnostic criteria.
“Nobody has yet shown that these measures beat existing screens, either on outcomes or on cost.”
— The authors of the paper
Tests and Benefits Still Unproven
The paper presents a proposed framework, not proof that motor-system assessments outperform existing screening or that changing diagnostic criteria will improve health. The authors say the suggested measures have not been shown to improve outcomes or reduce costs, and neuromuscular expertise is not equally available in primary care.
It also remains unclear which practical tests can reliably distinguish the different causes of weakness in routine care, and whether results would change treatment decisions. The supplied report does not provide trial evidence that medication review or any particular intervention prevents falls when used under this framework. The scale of benefit for patients, health services and fall rates is therefore unknown.
Validation Before Guideline Changes
The authors call for investment in studies that validate practical tests, guidelines that support a staged assessment approach, and trials that measure nerve as well as muscle. Those steps would help determine whether adding motor-system measures provides useful information beyond existing strength and mobility screens.
International working groups that develop sarcopenia diagnostic criteria are the intended audience for the proposed five-point agenda. The report does not give a timetable for a guideline revision or identify a scheduled decision. For now, the framework is a research proposal; whether it changes routine primary-care assessment will depend on validation and subsequent guidance.
Key Questions
What is the main claim of the new paper?
The authors argue that sarcopenia involves the aging motor system, including the brain, nerves and muscle, rather than being explained mainly by muscle loss.
Does the paper show that muscle loss is unimportant?
No. The paper does not say muscle is irrelevant. It argues that muscle loss explains only a modest proportion of age-related strength decline and that other parts of the motor system may also contribute.
Are the proposed tests ready for routine use?
Not on the evidence described in the report. The authors say the proposed measures have not been shown to outperform existing screens on outcomes or cost and call for validation.
Why does the issue matter for older adults?
Sarcopenia is associated with frailty, disability and loss of independence. A better understanding of why an individual is weak could eventually help clinicians target assessments and research, but benefits from this proposed approach have not yet been established.
Source: medicalxpress.com
